Fibronostics US, Inc.

Fibronostics US, Inc. is a pioneering healthcare technology company specializing in noninvasive medical diagnostics using artificial intelligence and advanced analytics for liver health assessment. Founded in 2015 and headquartered in Indian Harbour Beach, US, Fibronostics US, Inc. focuses on developing innovative diagnostic solutions.

The company has secured USD 6. 5 mn in funding through four deals, with the most recent deal occurring on June 15, 2022. The company is co-led by CEOs Roni Executive and Sven Henrichwark, and seeks to expand its product offerings and market presence. Fibronostics specializes in noninvasive medical diagnostics, offering innovative solutions that leverage artificial intelligence and advanced analytics to assess liver health.

Their flagship product, LIVERFASt™, is a blood-based test that analyzes ten specific biomarkers and patient anthropometric data to generate a score between 0. 00 and 1. 00, reflecting the patient's fibrosis, activity, and steatosis staging. This test is designed to provide healthcare professionals and patients with vital information about liver conditions without the need for invasive procedures like biopsies.

The product has been validated by leading clinicians and is applicable for various demographics, including individuals with metabolic diseases such as MASH and MASLD. Fibronostics markets its products across various regions, including the United States and select countries in Asia. Fibronostics generates revenue primarily through the sale of its flagship diagnostic test, LIVERFASt™, offered to healthcare providers such as hospitals, clinics, and individual practitioners. The transactions typically occur on a B2B basis, where physicians prescribe the LIVERFASt™ test to patients, and the company processes the blood samples in its CAP and CLIA-certified laboratory.

Results are delivered to healthcare providers via a digital portal or integrated systems. In the most recent year, the company reported revenue of USD 165,789 and an EBITDA of USD -1,975,914. In June 2022, Fibronostics US, Inc. raised USD 6.

5 mn in venture funding. The company plans to utilize this funding to further scale the commercialization of LIVERFASt in the U. S. and help develop its SaaS platform, as well as finance the research and development of new products targeting kidney and lung diseases.

Their strategy includes expanding into new markets and geographic regions beyond the U. S. , with specific target markets yet to be disclosed.